Guest: Carey Anders, MD, FASCO

Guest: Sarah Sammons, MD

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.00.